Last updated: 2026-09-05 19:07:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Sionna Therapeutics, Inc. (SION) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $7.20, with a market capitalization of $330.50M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.01 to $54.97. This page covers its latest market performance, valuation, price trends and company information.
$330.50M | |
$6.68 | |
$54.97 | |
$4.01 | |
$6.75 | |
744.86K | |
-- | |
-- | |
$54.97 | |
$4.01 | |
-- | |
-- |
Sionna Therapeutics, Inc. (SION) last closed at $6.75 as of 2026-09-04 23:50:00, unchanged from the previous close of $6.75.
During the latest regular trading session, SION traded between $4.01 and $54.97, with a volume of 744.86K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Sionna Therapeutics, Inc. (SION) moved from $5.87 to $7.20, representing a gain of 22.67% ($1.33).
The stock traded between $6.62 and $7.20 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 1.16 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 6.3%
SION is currently trading at $7.20, placing it 6.3% of the way from its 52-week low of $4.01 to its 52-week high of $54.97. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 59 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Sionna Therapeutics, Inc. (SION) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.